文献速递精神分裂症与精神病性障碍

肠道微生物组与精神分裂症治疗抵抗的关联

Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

这项病例对照研究纳入97名成人,采用鸟枪法宏基因组学分析肠道微生物组,并调整人口学与生活方式因素,发现微生物组与精神分裂症诊断及治疗抵抗存在显著关联,而氯氮平反应、便秘或代谢综合征的微生物组关联证据有限。

要点

  • 精神分裂症患者较对照组微生物丰富度显著降低,校正协变量与多重比较后仍显著。
  • 微生物组与精神分裂症诊断及治疗抵抗在多个分类和功能水平上存在显著关联。
  • 氯氮平反应、便秘或代谢综合征与微生物组的关联证据有限。

核心结论

  • 研究结果与氯氮平改变肠道微生物组组成的观点一致,但不能排除预先存在的微生物组差异促成治疗抵抗的可能性。

研究设计与样本

  • 病例对照研究纳入97名20至63岁成人,收集粪便样本及人口学、生活方式和用药数据,采用鸟枪法宏基因组学检测肠道微生物组。

主要发现

  • 治疗抵抗与微生物组显著关联,例如常见物种b2为27%,SE为16%,校正P=0.03。
  • 在精神分裂症个体中发现19种差异丰富的细菌物种和162条代谢通路,主要与治疗抵抗和氯氮平暴露相关。

关键数值与推荐

  • 微生物组与氯氮平反应、便秘或代谢综合征的关联证据有限。

临床怎么用

  • 未来研究应纳入用药和生活方式变量,以解释慢性精神分裂症患者微生物组改变的既往报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is growing interest in the role of gut microbiome composition in schizophrenia. However, lifestyle factors are often neglected, and few studies have investigated microbiome composition in treatment-resistant schizophrenia. OBJECTIVE: To explore associations between the gut microbiome and schizophrenia diagnosis, treatment resistance, clozapine response, and treatment-related adverse effects while adjusting for demographic and lifestyle factors. DESIGN, SETTING, AND PARTICIPANTS: In this case-control study of adults aged 20 to 63 years, stool samples and data on demographic characteristics, lifestyle, and medication use were collected and gut microbiome measures obtained using shotgun metagenomics. Participants with a schizophrenia diagnosis were referred through psychiatric inpatient units and outpatient clinics. Data were collected for 4 distinct groups: control individuals without a psychiatric diagnosis (past or present), individuals with treatment-responsive schizophrenia taking nonclozapine antipsychotic medications, clozapine-responsive individuals with treatment-resistant schizophrenia, and clozapine-nonresponsive individuals with treatment-resistant schizophrenia. Participants were recruited between November 2020 and November 2021. Control individuals were recruited in parallel through posters and online advertisements and matched for age, sex, and body mass index (BMI) to the individuals with schizophrenia. Participants were excluded if taking antibiotics in the past 2 months, if unable to communicate in English or otherwise follow study instructions, were pregnant or planning to become pregnant, or had any concomitant disease or condition making them unsuited to the study per investigator assessment. Data were analyzed from January 2022 to March 2023. MAIN OUTCOMES AND MEASURES: Omics relationship matrices, α and β diversity, and relative abundance of microbiome features. RESULTS: Data were collected for 97 individuals (71 [74%] male; mean [SD] age, 40.4 [10.3] years; mean [SD] BMI, 32.8 [7.4], calculated as weight in kilograms divided by height in meters squared). Significant microbiome associations with schizophrenia were observed at multiple taxonomic and functional levels (eg, common species: b2, 30%; SE, 13%; adjusted P = .002) and treatment resistance (eg, common species: b2, 27%; SE, 16%; adjusted P = .03). In contrast, limited evidence was found for microbiome associations with clozapine response, constipation, or metabolic syndrome. Significantly decreased microbial richness was found in individuals with schizophrenia compared to control individuals (t95 = 4.25; P < .001; mean [SD] for control individuals, 151.8 [32.31]; mean [SD] for individuals with schizophrenia, 117.00 [36.2]; 95% CI, 18.6-51.0), which remained significant after a covariate and multiple comparison correction. However, limited evidence was found for differences in β diversity (weighted UniFrac) for schizophrenia diagnosis (permutational multivariate analysis of variance [PERMANOVA]: R2, 0.03; P = .02), treatment resistance (R2, 0.02; P = .18), or clozapine response (R2, 0.04; P = .08). Multiple differentially abundant bacterial species (19) and metabolic pathways (162) were found in individuals with schizophrenia, which were primarily associated with treatment resistance and clozapine exposure. CONCLUSIONS AND RELEVANCE: The findings in this study are consistent with the idea that clozapine induces alterations to gut microbiome composition, although the possibility that preexisting microbiome differences contribute to treatment resistance cannot be ruled out. These findings suggest that prior reports of microbiome alterations in individuals with chronic schizophrenia may be due to medication or lifestyle factors and that future studies should incorporate these variables in their design and interpretation.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Vasileva SS, Yang Y, Baker A, et al. Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia. JAMA Psychiatry. 2024. PMID: 38294805. doi:10.1001/jamapsychiatry.2023.5371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。